series-b
Stage
2016
Founded
3
Investors
About
Confo Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies targeting G-protein coupled receptors (GPCRs) for metabolic and endocrine diseases. The company utilizes its proprietary ConfoBody® technology to stabilize GPCRs in active conformations, enabling the discovery and development of small molecule and antibody-based therapeutics.
Explore Confo Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.